MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer's disease

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Denk, Johannes ^a   Boelmans, Kai ^a   Siegismund, Christine ^b   Lassner, Dirk ^b   Arlt, Sönke ^a   Jahn, Holger ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute of Cardiac Diagnostics and Therapy (IKDT)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE 1; BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 100; MICRORNA 103; MICRORNA 1274A; MICRORNA 146A; MICRORNA 219; MICRORNA 296; MICRORNA 3622B 3P; MICRORNA 375; MICRORNA 4467; MICRORNA 505; MICRORNA 708; MICRORNA 766; TAU PROTEIN; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; MIRN100 MICRORNA, HUMAN; MIRN103 MICRORNA, HUMAN; MIRN375 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; SECRETASE; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MALE; SIGNAL TRANSDUCTION; UPREGULATION; CEREBROSPINAL FLUID; DISCRIMINANT ANALYSIS; DNA MICROARRAY; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BIOMARKERS; DISCRIMINANT ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TAU PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84930677807     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126423     Document Type: Article

References (71)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006; 368(9533):387-403. PMID: 16876668
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiological reviews. 2001; 81(2):741-66. PMID: 11274343
3. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid((1-42)) and tau levels in CSF. Neurology. 1999; 52(8):1555-62. PMID: 10331678
4. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010; 56(2):248-53. doi: 10.1373/clinchem.2009.130518 PMID: 19833838
5. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free radical biology & medicine. 2009; 46(9):1241-9.
6. Migliore L, Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutation research. 2009; 667(1-2):82-97. doi: 10.1016/j.mrfmmm.2009.02.002 PMID: 19563929
7. Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, Verhey F, et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Progress in neurobiology. 2010; 90(4):498-510. doi: 10.1016/j.pneurobio.2010.01.002 PMID: 20097254
8. Maciotta S, Meregalli M, Torrente Y. The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci. 2013; 7:265. doi: 10.3389/fncel.2013.00265 PMID: 24391543
9. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9(2):102-14. doi: 10.1038/nrg2290 PMID: 18197166
10. st ed. Berlin: Springer-Verlag; 2010.
11. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, et al. A brain-specific microRNA regulates dendritic spine development. Nature. 2006; 439(7074):283-9. PMID: 16421561
12. Gao J, Wang WY, Mao YW, Graff J, Guan JS, Pan L, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010; 466(7310):1105-9. doi: 10.1038/nature09271 PMID: 20622856
13. Abdelmohsen K, Hutchison ER, Lee EK, Kuwano Y, Kim MM, Masuda K, et al. miR-375 inhibits differentiation of neurites by lowering HuD levels. Mol Cell Biol. 2010; 30(17):4197-210. doi: 10.1128/MCB.00316-10 PMID: 20584986
14. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport. 2007; 18(3):297-300. PMID: 17314675
15. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer's disease: JAD. 2008; 14(1):27-41. PMID: 18525125
16. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008; 105(17):6415-20. doi: 10.1073/pnas.0710263105 PMID: 18434550
17. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol. 2002; 51(6):783-6. PMID: 12112088
18. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008; 28(5):1213-23. doi: 10.1523/JNEUROSCI.5065-07.2008 PMID: 18234899
19. Liu W, Liu C, Zhu J, Shu P, Yin B, Gong Y, et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiology of aging. 2012; 33(3):522-34. doi: 10.1016/j.neurobiolaging.2010.04.034 PMID: 20619502
20. Koberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bonig H, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One. 2013; 8(9):e75184. doi: 10.1371/journal.pone.0075184 PMID: 24073250
21. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem. 2010; 56(6):998-1006. doi: 10.1373/clinchem.2009.141580 PMID: 20378769
22. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733-41. doi: 10.1373/clinchem.2010.147405 PMID: 20847327
23. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Critical reviews in oncology/hematology. 2011; 80(2):193-208. doi: 10.1016/j.critrevonc.2010.11.004 PMID: 21145252
24. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutation research. 2011; 717(1-2):85-90. doi: 10.1016/j.mrfmmm.2011.07.020 PMID: 21889945
25. Machida A, Ohkubo T, Yokota T. Circulating microRNAs in the cerebrospinal fluid of patients with brain diseases. Methods Mol Biol. 2013; 1024:203-9. doi: 10.1007/978-1-62703-453-1-16 PMID: 23719953
26. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014; 18(3):371-90. doi: 10.1111/jcmm.12236 PMID: 24533657
27. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012; 13(5):358-69. doi: 10.1038/nrg3198 PMID: 22510765
28. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. doi: 10.1373/clinchem.2008.112797 PMID: 19246619
29. World Health Organisation. ICD-10: international statistical classification of diseases and related health problems. Geneva: World Health Organisation; 1992.
30. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-46. PMID: 17616482
31. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011; 7(3):257-62.
32. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011; 7(3):263-9.
33. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011; 7(3):280-92.
34. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011; 7(3):270-9.
35. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2012; 8(1):1-13.
36. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(Pt 9):2456-77. doi: 10.1093/brain/awr179 PMID: 21810890
37. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76(11):1006-14. doi: 10.1212/WNL.0b013e31821103e6 PMID: 21325651
38. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. PMID: 15324362
39. Lewczuk P, Kornhuber J, Wiltfang J. The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm. 2006; 113(8):1075-80. PMID: 16835693
40. Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M. A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines. Methods. 2010; 50(4):S1-5. doi: 10.1016/j.ymeth.2010.01.005 PMID: 20215014
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8. PMID: 11846609
42. Yassouridis A, Ludwig T, Steiger A, Leisch F. A new way of identifying biomarkers in biomedical basic-research studies. PLoS One. 2012; 7(5):e35741. doi: 10.1371/journal.pone.0035741 PMID: 22606233
43. Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A, et al. Transcriptional landscape of the prenatal human brain. Nature. 2014; 508(7495):199-206. doi: 10.1038/nature13185 PMID: 24695229
44. Ziats MN, Rennert OM. Identification of differentially expressed microRNAs across the developing human brain. Mol Psychiatry. 2014; 19(7):848-52. doi: 10.1038/mp.2013.93 PMID: 23917947
45. Blennow K, Vanmechelen E, Hampel H. CSF total tau, a beta 42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Molecular Neurobiology. 2001; 24(1-3):87-97. PMID: 11831557
46. Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Frontiers in genetics. 2013; 4:150. doi: 10.3389/fgene.2013.00150 PMID: 23964286
47. Sala Frigerio C, Lau P, Salta E, Tournoy J, Bossers K, Vandenberghe R, et al. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology. 2013; 81(24):2103-6. doi: 10.1212/01.wnl.0000437306.37850.22 PMID: 24212398
48. Sheinerman KS, Umansky SR. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci. 2013; 7:150. doi: 10.3389/fncel.2013.00150 PMID: 24058335
49. Chen Y, Gelfond JA, McManus LM, Shireman PK. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics. 2009; 10:407. doi: 10.1186/1471-2164-10-407 PMID: 19715577
50. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011; 18(10):1139-46. doi: 10.1038/nsmb.2115 PMID: 21909094
51. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell. 2013; 12(3):370-80. doi: 10.1111/acel.12057 PMID: 23425014
52. Schopman NC, Heynen S, Haasnoot J, Berkhout B. A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. Rna Biol. 2010; 7(5):573-6. doi: 10.4161/rna.7.4.13141 PMID: 20818168
53. Antony JM, Deslauriers AM, Bhat RK, Ellestad KK, Power C. Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? Biochimica et biophysica acta. 2011; 1812(2):162-76. doi: 10.1016/j.bbadis.2010.07.016 PMID: 20696240
54. Lukiw WJ. NF-kappaB-regulated, proinflammatory miRNAs in Alzheimer's disease. Alzheimer's research & therapy. 2012; 4(6):47.
55. Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Current gerontology and geriatrics research. 2012; 2012:170276. doi: 10.1155/2012/170276 PMID: 22454637
56. Alexandrov PN, Dua P, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ. microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol. 2012; 3(4):365-73. PMID: 23301201
57. Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem. 2008; 283(46):31315-22. doi: 10.1074/jbc.M805371200 PMID: 18801740
58. Li YY, Cui JG, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ. Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models. Neuroscience letters. 2011; 487(1):94-8. doi: 10.1016/j.neulet.2010.09.079 PMID: 20934487
59. Sethi P, Lukiw WJ. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neuroscience letters. 2009; 459(2):100-4. doi: 10.1016/j.neulet.2009.04.052 PMID: 19406203
60. Coolen M, Katz S, Bally-Cuif L. miR-9: a versatile regulator of neurogenesis. Front Cell Neurosci. 2013; 7:220. doi: 10.3389/fncel.2013.00220 PMID: 24312010
61. Schonrock N, Matamales M, Ittner LM, Gotz J. MicroRNA networks surrounding APP and amyloid-beta metabolism - implications for Alzheimer's disease. Experimental neurology. 2012; 235(2):447-54. doi: 10.1016/j.expneurol.2011.11.013 PMID: 22119426
62. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013; 14(7):R78. doi: 10.1186/gb-2013-14-7-r78 PMID: 23895045
63. Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER, et al. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers. 2013; 18(5):455-66. doi: 10.3109/1354750X.2013.814073 PMID: 23822153
64. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2014; 39(2):253-9. doi: 10.3233/JAD-130932 PMID: 24157723
65. Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiology of aging. 2014; 35(1):152-8. doi: 10.1016/j.neurobiolaging.2013.07.005 PMID: 23962497
66. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014; 11(8):809-15. doi: 10.1038/nmeth.3014 PMID: 24973947
67. Le Carre J, Lamon S, Leger B. Validation of a multiplex reverse transcription and pre-amplification method using TaqMan((R)) MicroRNA assays. Frontiers in genetics. 2014; 5:413. doi: 10.3389/fgene.2014.00413 PMID: 25505484
68. Rosa-Neto P, Hsiung GY, Masellis M, participants C. Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. Alzheimer's research & therapy. 2013; 5(Suppl 1):S8.
69. Baker M. MicroRNA profiling: separating signal from noise. Nat Methods. 2010; 7(9):687-92. doi: 10.1038/nmeth0910-687 PMID: 20805796
70. Lau P, Frigerio CS, De Strooper B. Variance in the identification of microRNAs deregulated in Alzheimer's disease and possible role of lincRNAs in the pathology: the need of larger datasets. Ageing Res Rev. 2014; 17:43-53. doi: 10.1016/j.arr.2014.02.006 PMID: 24607832
71. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2012; 8(1):65-73.